NMRA Stock Forecast & Price Target

Neumora Therapeutics is a clinical-stage biopharmaceutical company with a strong pipeline of seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for a range of neuropsychiatric disorders and neurodegenerative diseases. Despite the recent discontinuation of navacaprant development following disappointing Phase 3 results, the company's pipeline and potential for value creation remain strong. Upcoming key milestones for the pipeline include NMRA-511's MAD data in 4Q26, NMRA-898's Ph 1 data in 2H26, and an obesity program update at the August earnings call. Despite the setbacks with navacaprant, Neumora continues to hold value through its diverse pipeline and we maintain a positive outlook on the company's potential.

Neumora Therapeutics is facing a negative outlook due to the failure of its lead asset, navacaprant, in the Phase 3 KOASTAL-2 and -3 studies for the treatment of major depressive disorder. This has led to the company discontinuing development of the drug and focusing on other assets in its pipeline, such as NMRA-898, NMRA-511, and NMRA-215. However, the company's decision to reduce workforce and restructure costs may provide some cost savings, but it is still a long way from generating any meaningful revenue. Furthermore, with a runway only until 3Q27, there is uncertainty about the company's ability to sustain itself until key readouts in the next 12-18 months.